AG Falk Nimmerjahn

Focus of research: AG Falk Nimmerjahn

The group of Professor Falk Nimmerjahn is interested in antibody-mediated effector functions and mechanisms of humoral tolerance.



Prof. Dr. Falk Nimmerjahn

Lehrstuhl für Genetik (Prof. Nimmerjahn)

<< Staff of the Nimmerjahn group >>

Immune responses and the cells involved are regulated through a variety of activating and inhibitory signals. Marginal discrepancies in this balance can lead to either too weak or too diligent immune responses. This dysregulation can have severe consequences, such as uncontrolled infections with pathogenic microorganisms on the one hand, or the initiation of auto immune diseases on the other.

Antibodies play important roles in both scenarios, as they are involved both in the bodies immune defense as well as the destruction of healthy tissue, in the context of autoimmunity. Therefore, the production of antibodies in the body is tightly controlled at multiple checkpoints (Fig. 1).

Fig. 1: Checkpoints of the humoral immune system (Nimmerjahn & Ravetch, Nature Reviews Immunology 2008)

An important factor herein is the regulation of signals stemming from the BCR. Lack of several proteins has been associated with dysregulation of the B cell response. In our previous studies, we could show, that the inhibitory Fc receptor FcgRIIB acts as a crucial checkpoint in late B cell developmental stages.

Studies on SLE patients, combined with our own results of work on CIDP (chronic immune-mediated demyelinating polyneuropathy) patients, have underlined the importance of this negative regulation also in the human context. Beside classic mouse models, we also utilize novel humanized mouse models, which allow us to assess the translatability of our results to the human immune system.

Fig. 2: Interaction of immune complexes with cells of the innate and adaptive immune system (Nimmerjahn & Ravetch, Nature Reviews Immunology 2008)


The starting point of our studies has been the observation, that certain IgG subclasses are more capable of mediating the destruction of healthy tissues in the context of auto immune disease, and tumor cells in the context of immunotherapy. We could show that functional inactivation of all murine Fc receptors abrogates activity of all IgG subclasses in vivo. During our studies, we identified FcgRIV as a novel activating Fc receptor predominantly expressed on neutrophils and monocytes, that specifically binds IgG2a and IgG2b.
For the first time, we managed to map the functional activity of all IgG subclasses to their respective activating Fc receptors.

In follow-up studies, these insights could be translated onto other model systems, such as e.g. therapeutically relevant tumor models. Those insights are not only of great importance for the murine system, but are also of value for the human immune system, since FcgRIV could be identified as the then unknown orthologue to human FcgRIIIa, a receptor that plays integral roles in effector functions of therapeutic antibodies.

On the foundation of this preliminary data, we are currently trying to identify cell populations, that are responsible for IgG/Fc receptor mediated effector functions (Fig. 2).

Another focus of our research lies in the functional analysis of antibody glycosylation variants. Each IgG molecule consists, beside the protein backbone, of a sugar chain, which itself is made up of a central lattice and a variable number of terminal and branched sugar residues such as fucose, sialic acid or galactose. Beside their long-known function in ensuring correct antibody folding, these glycosylation variants also heavily impact antibody functionality.

This has big implications for the usage of such antibody variants in the therapy of malignant diseases, but also for the use of anti-inflammatory IgG preparations in the context of auto immune diseases (IVIg-therapy). We try to assess this IgG-mediated anti-inflammatory mechanism in a variety of projects.

Falk Nimmerjahn on Google Scholar

5 Key Publications

  1. Lehmann, B., M. Biburger, C. Brückner, A. Ipsen-Escobedo, S. Gordan, C. Lehmann, D. Voehringer, T. Winkler, N. Schaft, D. Dudziak, H. Sirbu, G.F. Weber, and F. Nimmerjahn. 2017. Tumor location determines tissue-specific recruitmetn of tumor-associated macrophages and antibody-dependent immunotherapy response. Science Immunol 2:1-11.
  2. Kao, D., H. Danzer, M. Collin, A. Gross, J. Eichler, J. Stambuk, G. Lauc, A. Lux, and F. Nimmerjahn. 2015. A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep 13:2376-2385.
  3. Nimmerjahn, F., S. Gordan, and A. Lux. 2015. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 36:325-336.
  4. Schwab, I., A. Lux, and F. Nimmerjahn. 2015. Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. Cell Rep 13:610-620.
  5. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35:932-944.

Primary Publications (since 2012)

  • Lehmann, C., A. Baranska, G. Heidkamp, L. Heger, K. Neubert, J. Lühr, A. Hoffmann, K.C. Reimer, C. Brückner, S. Beck, M. Seeling, M. Kiessling, D. Soulat, A.B. Krug, J.V. Ravetch, J.H. Leusen, F. Nimmerjahn, and D. Dudziak. 2017. DC subset specific induction of T cell responses upon antigen uptake via Fc receptors in vivo. J Exp Med in press.
  • Lehmann, B., M. Biburger, C. Brückner, A. Ipsen-Escobedo, S. Gordan, C. Lehmann, D. Voehringer, T. Winkler, N. Schaft, D. Dudziak, H. Sirbu, G.F. Weber, and F. Nimmerjahn. 2017. Tumor location determines tissue-specific recruitmetn of tumor-associated macrophages and antibody-dependent immunotherapy response. Science Immunol 2:1-11.
  • Pfeifle, R., T. Rothe, N. Ipseiz, H.U. Scherer, S. Culemann, U. Harre, J.A. Ackermann, M. Seefried, A. Kleyer, S. Uderhardt, B. Haugg, A.J. Hueber, P. Daum, G.F. Heidkamp, C. Ge, S. Bohm, A. Lux, W. Schuh, I. Magorivska, K.S. Nandakumar, E. Lonnblom, C. Becker, D. Dudziak, M. Wuhrer, Y. Rombouts, C.A. Koeleman, R. Toes, T.H. Winkler, R. Holmdahl, M. Herrmann, S. Bluml, F. Nimmerjahn, G. Schett, and G. Kronke. 2017. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nature Immunol 18:104-113.
  • Hartholt, R.B., A. Wroblewska, E. Herczenik, I. Peyron, A. Ten Brinke, T. Rispens, M.A. Nolte, E. Slot, J.W. Claassens, F. Nimmerjahn, J.S. Verbeek, and J. Voorberg. 2017. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost15:329-340.
  • Van den Hoecke, S., K. Ehrhardt, A. Kolpe, K. El Bakkouri, L. Deng, H. Grootaert, S. Schoonooghe, A. Smet, M. Bentahir, K. Roose, M. Schotsaert, B. Schepens, N. Callewaert, F. Nimmerjahn, P. Staeheli, H. Hengel, and X. Saelens. 2017. Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies. J Virol
  • Wege, A.K., F. Weber, A. Kroemer, O. Ortmann, F. Nimmerjahn, and G. Brockhoff. 2017. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 8:2731-2744.
  • Brandsma, A.M., P.M. Hogarth, F. Nimmerjahn, and J.H. Leusen. 2016. Clarifying the Confusion between Cytokine and Fc Receptor „Common Gamma Chain“. Immunity 45:225-226.
  • Hartholt, R.B., A. Wroblewska, E. Herczenik, I. Peyron, A. Ten Brinke, T. Rispens, M.A. Nolte, E. Slot, J.W. Claassens, F. Nimmerjahn, J.S. Verbeek, and J. Voorberg. 2016. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost
  • Heidkamp, G., J. Sander, C. Lehmann, L. Heger, N. Eissing, A. Lux, S. Söder, A. Hartmann, J. Zenk, T. Ulas, N. McGovern, C. Alexiou, B.M. Spriewald, A. Mackensen, G. Schuler, B. Schauf, A. Forster, R. Repp, P.A. Fasching, A. Purbojo, R. Cesnjevar, E. Ullrich, F. Ginhoux, A. Schlitzer, F. Nimmerjahn, J.L. Schultze, and D. Dudziak. 2016. Human Lymphoid Organ Dendritic Cell Identity is predominantly dictated by ontogeny, not tissue microenvironment. Science Immunol 12:1-17.
  • Magorivska, I., L.E. Munoz, C. Janko, T. Dumych, J. Rech, G. Schett, F. Nimmerjahn, R. Bilyy, and M. Herrmann. 2016. Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells. Clin Exp Immunol 184:110-117.
  • Mihai, S., H. Albert, R.J. Ludwig, H. Iwata, L. Bjorck, M. Collin, and F. Nimmerjahn. 2016. In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury. Exp Dermatol
  • Nimmerjahn, F. 2016. Immunomodulation of immunothrombocytopenia. Semin Hematol 53 Suppl 1:S10-12.
  • Nimmerjahn, F. 2016. Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches. J Clin Immunol 36 Suppl 1:83-87.
  • Ortiz, D.F., J.C. Lansing, L. Rutitzky, E. Kurtagic, T. Prod’homme, A. Choudhury, N. Washburn, N. Bhatnagar, C. Beneduce, K. Holte, R. Prenovitz, M. Child, J. Killough, S. Tyler, J. Brown, S. Nguyen, I. Schwab, M. Hains, R. Meccariello, L. Markowitz, J. Wang, R. Zouaoui, A. Simpson, B. Schultes, I. Capila, L. Ling, F. Nimmerjahn, A.M. Manning, and C.J. Bosques. 2016. Elucidating the interplay between IgG-Fc valency and FcgammaR activation for the design of immune complex inhibitors. Science Transl Med 8:365ra158.
  • Stamatiades, E.G., M.E. Tremblay, M. Bohm, L. Crozet, K. Bisht, D. Kao, C. Coelho, X. Fan, W.T. Yewdell, A. Davidson, P.S. Heeger, S. Diebold, F. Nimmerjahn, and F. Geissmann. 2016. Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. Cell166:991-1003.
  • Biburger, M., I. Trenkwald, and F. Nimmerjahn. 2015. Three blocks are not enough–Blocking of the murine IgG receptor FcgammaRIV is crucial for proper characterization of cells by FACS analysis. Eur J Immunol 45:2694-2697.
  • Bruhl, H., J. Cihak, Y. Talke, M. Rodriguez Gomez, F. Hermann, N. Goebel, K. Renner, J. Plachy, M. Stangassinger, S. Aschermann, F. Nimmerjahn, and M. Mack. 2015. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis. Eur J Immunol 45:705-715.
  • Fickentscher, C., I. Magorivska, C. Janko, M. Biermann, R. Bilyy, C. Nalli, A. Tincani, V. Medeghini, A. Meini, F. Nimmerjahn, G. Schett, L.E. Munoz, L. Andreoli, and M. Herrmann. 2015. The Pathogenicity of Anti-beta2GP1-IgG Autoantibodies Depends on Fc Glycosylation. J Immunol Res 2015:638129
  • Gordan, S., M. Biburger, and F. Nimmerjahn. 2015. bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. Immunol Rev 268:52-65.
  • Harre, U., S.C. Lang, R. Pfeifle, Y. Rombouts, S. Fruhbeisser, K. Amara, H. Bang, A. Lux, C.A. Koeleman, W. Baum, K. Dietel, F. Grohn, V. Malmstrom, L. Klareskog, G. Kronke, R. Kocijan, F. Nimmerjahn, R.E. Toes, M. Herrmann, H.U. Scherer, and G. Schett. 2015. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nature Commun 6:6651.
  • Hasenberg, A., M. Hasenberg, L. Mann, F. Neumann, L. Borkenstein, M. Stecher, A. Kraus, D.R. Engel, A. Klingberg, P. Seddigh, Z. Abdullah, S. Klebow, S. Engelmann, A. Reinhold, S. Brandau, M. Seeling, A. Waisman, B. Schraven, J.R. Gothert, F. Nimmerjahn, and M. Gunzer. 2015. Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. Nature Methods 12:445-452.
  • Hirose, M., B. Tiburzy, N. Ishii, E. Pipi, S. Wende, E. Rentz, F. Nimmerjahn, D. Zillikens, R.A. Manz, R.J. Ludwig, and M. Kasperkiewicz. 2015. Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita. J Invest Dermatol 135:768-775.
  • Kao, D., H. Danzer, M. Collin, A. Gross, J. Eichler, J. Stambuk, G. Lauc, A. Lux, and F. Nimmerjahn. 2015. A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Rep 13:2376-2385.
  • Lunemann, J.D., F. Nimmerjahn, and M.C. Dalakas. 2015. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nature Rev Neurol 11:80-89.
  • Lux, A., and F. Nimmerjahn. 2015. No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer. Cancer Cell 27:10-11.
  • Muller, J., B. Lunz, I. Schwab, A. Acs, F. Nimmerjahn, C. Daniel, and L. Nitschke. 2015. Siglec-G Deficiency Leads to Autoimmunity in Aging C57BL/6 Mice. J Immunol 195:51-60.
  • Nimmerjahn, F. 2015. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. Eur J Immunol 45:2183-2190.
  • Nimmerjahn, F., S. Gordan, and A. Lux. 2015. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 36:325-336.
  • Quast, I., F. Cueni, F. Nimmerjahn, B. Tackenberg, and J.D. Lunemann. 2015. Deregulated Fcgamma receptor expression in patients with CIDP. Neurol Neuroimmunol Neuroinflamm 2:e148.
  • Quast, I., C.W. Keller, M.A. Maurer, J.P. Giddens, B. Tackenberg, L.X. Wang, C. Munz, F. Nimmerjahn, M.C. Dalakas, and J.D. Lunemann. 2015. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125:4160-4170.
  • Schwab, I., A. Lux, and F. Nimmerjahn. 2015. Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. Cell Rep 13:610-620.
  • Seeling, M., and F. Nimmerjahn. 2015. Releasing the brakes: targeting FcgammaRIIB on B cells to enhance antibody-dependent lymphoma immunotherapy. Cancer Cell 27:427-428.
  • Seeling, M., and F. Nimmerjahn. 2015. Unlocking the bone: Fcgamma-receptors and antibody glycosylation are keys to connecting bone homeostasis to humoral immunity. Ann Transl Med 3:163.
  • Stock, M., A. Distler, J. Distler, C. Beyer, G. Ruiz-Heiland, N. Ipseiz, M. Seeling, G. Kronke, F. Nimmerjahn, and G. Schett. 2015. Fc-gamma receptors are not involved in cartilage damage during experimental osteoarthritis. Osteoarthritis Cartilage 23:1221-1225.
  • Washburn, N., I. Schwab, D. Ortiz, N. Bhatnagar, J.C. Lansing, A. Medeiros, S. Tyler, D. Mekala, E. Cochran, H. Sarvaiya, K. Garofalo, R. Meccariello, J.W. Meador, 3rd, L. Rutitzky, B.C. Schultes, L. Ling, W. Avery, F. Nimmerjahn, A.M. Manning, G.V. Kaundinya, and C.J. Bosques. 2015. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 112:E1297-1306.
  • Yamada, D.H., H. Elsaesser, A. Lux, J.M. Timmerman, S.L. Morrison, J.C. de la Torre, F. Nimmerjahn, and D.G. Brooks. 2015. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42:379-390.
    Biburger, M., A. Lux, and F. Nimmerjahn. 2014. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv Immunol 124:67-94.
  • Bohm, S., D. Kao, and F. Nimmerjahn. 2014. Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. Curr Top Microbiol Immunol 382:393-417.
  • Daeron, M., and F. Nimmerjahn. 2014. High amounts of specific antibodies are produced upon antigen stimulation during adaptive immune responses. Preface. Curr Top Microbiol Immunol 382:v – xi.
  • Kao, D., A. Lux, I. Schwab, and F. Nimmerjahn. 2014. Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin Immunopathol 36:289-299.
  • Lux, A., M. Seeling, A. Baerenwaldt, B. Lehmann, I. Schwab, R. Repp, N. Meidenbauer, A. Mackensen, A. Hartmann, G. Heidkamp, D. Dudziak, and F. Nimmerjahn. 2014. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep 7:236-248.
  • Neubert, K., C.H. Lehmann, L. Heger, A. Baranska, A.M. Staedtler, V.R. Buchholz, S. Yamazaki, G.F. Heidkamp, N. Eissing, H. Zebroski, M.C. Nussenzweig, F. Nimmerjahn, and D. Dudziak. 2014. Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. J Immunol192:5830-5838.
  • Nimmerjahn, F., and A. Lux. 2014. LILR-B1 blocks activating FcgammaR signaling to allow antibody dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 111:2404-2405.
  • Schulze, F.S., T. Beckmann, F. Nimmerjahn, A. Ishiko, M. Collin, J. Kohl, S. Goletz, D. Zillikens, R. Ludwig, and E. Schmidt. 2014. Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 184:2185-2196.
    Schwab, I., A. Lux, and F. Nimmerjahn. 2014. Reply to – IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Rev Immunol 14:349.
  • Schwab, I., S. Mihai, M. Seeling, M. Kasperkiewicz, R.J. Ludwig, and F. Nimmerjahn. 2014. Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol44:1444-1453.
    Schwab, I., and F. Nimmerjahn. 2014. Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin – F(ab‘)(2) versus Fc sialylation. Clin Exp Immunol178 Suppl 1:97-99.
  • Schwartz, C., A. Turqueti-Neves, S. Hartmann, P. Yu, F. Nimmerjahn, and D. Voehringer. 2014. Basophil-mediated protection against gastrointestinal helminths requires IgE-induced cytokine secretion. Proc Natl Acad Sci U S A 111:E5169-5177.
  • Toh, M.L., J.Y. Bonnefoy, N. Accart, S. Cochin, S. Pohle, H. Haegel, M. De Meyer, C. Zemmour, X. Preville, C. Guillen, C. Thioudellet, P. Ancian, A. Lux, B. Sehnert, F. Nimmerjahn, R.E. Voll, and G. Schett. 2014. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. Arthritis Rheumatol 66:2989-3000.
  • Aschermann, S., C.H. Lehmann, S. Mihai, G. Schett, D. Dudziak, and F. Nimmerjahn. 2013. B cells are critical for autoimmune pathology in Scurfy mice. Proc Natl Acad Sci U S A 110:19042-19047.
  • Glorius, P., A. Baerenwaldt, C. Kellner, M. Staudinger, M. Dechant, M. Stauch, F.J. Beurskens, P.W. Parren, J.G. Winkel, T. Valerius, A. Humpe, R. Repp, M. Gramatzki, F. Nimmerjahn, and M. Peipp. 2013. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia27:190-201.
  • Lux, A., and F. Nimmerjahn. 2013. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol 33 Suppl 1:S4-8.
  • Lux, A., X. Yu, C.N. Scanlan, and F. Nimmerjahn. 2013. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 190:4315-4323.
  • Mihai, S., and F. Nimmerjahn. 2013. The role of Fc receptors and complement in autoimmunity. Autoimmun Rev 12:657-660.
  • Schwab, I., and F. Nimmerjahn. 2013. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature Rev Immunol 13:176-189.
  • Seeling, M., U. Hillenhoff, J.P. David, G. Schett, J. Tuckermann, A. Lux, and F. Nimmerjahn. 2013. Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A110:10729-10734.
  • Sehnert, B., H. Burkhardt, J.T. Wessels, A. Schroder, M.J. May, D. Vestweber, J. Zwerina, K. Warnatz, F. Nimmerjahn, G. Schett, S. Dubel, and R.E. Voll. 2013. NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A 110:16556-16561.
  • Straub, T., O. Schweier, M. Bruns, F. Nimmerjahn, A. Waisman, and H. Pircher. 2013. Nucleoprotein-specific nonneutralizing antibodies speed up LCMV elimination independently of complement and FcgammaR. Eur J Immunol 43:2338-2348.
  • Biburger, M., and F. Nimmerjahn. 2012. Low level of FcgammaRIII expression on murine natural killer cells. Immunol Lett 143:53-59.
    Bohm, S., I. Schwab, A. Lux, and F. Nimmerjahn. 2012. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 34:443-453.
  • Harre, U., D. Georgess, H. Bang, A. Bozec, R. Axmann, E. Ossipova, P.J. Jakobsson, W. Baum, F. Nimmerjahn, E. Szarka, G. Sarmay, G. Krumbholz, E. Neumann, R. Toes, H.U. Scherer, A.I. Catrina, L. Klareskog, P. Jurdic, and G. Schett. 2012. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791-1802.
  • Herrmann, M., C. Schafer, A. Heiss, S. Graber, A. Kinkeldey, A. Buscher, M.M. Schmitt, J. Bornemann, F. Nimmerjahn, L. Helming, S. Gordon, and W. Jahnen-Dechent. 2012. Clearance of fetuin-A–containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 111:575-584.
  • Karsten, C.M., M.K. Pandey, J. Figge, R. Kilchenstein, P.R. Taylor, M. Rosas, J.U. McDonald, S.J. Orr, M. Berger, D. Petzold, V. Blanchard, A. Winkler, C. Hess, D.M. Reid, I.V. Majoul, R.T. Strait, N.L. Harris, G. Kohl, E. Wex, R. Ludwig, D. Zillikens, F. Nimmerjahn, F.D. Finkelman, G.D. Brown, M. Ehlers, and J. Kohl. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nature Med 18:1401-1406.
  • Kasperkiewicz, M., F. Nimmerjahn, S. Wende, M. Hirose, H. Iwata, M.F. Jonkman, U. Samavedam, Y. Gupta, S. Moller, E. Rentz, L. Hellberg, K. Kalies, X. Yu, E. Schmidt, R. Hasler, T. Laskay, J. Westermann, J. Kohl, D. Zillikens, and R.J. Ludwig. 2012. Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury. J Pathol 228:8-19.
  • Lehmann, B., I. Schwab, S. Bohm, A. Lux, M. Biburger, and F. Nimmerjahn. 2012. FcgammaRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol8:243-254.
  • Lopez-Parra, V., B. Mallavia, O. Lopez-Franco, G. Ortiz-Munoz, A. Oguiza, C. Recio, J. Blanco, F. Nimmerjahn, J. Egido, and C. Gomez-Guerrero. 2012. Fcgamma receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 23:1518-1527.
  • Moldt, B., M. Shibata-Koyama, E.G. Rakasz, N. Schultz, Y. Kanda, D.C. Dunlop, S.L. Finstad, C. Jin, G. Landucci, M.D. Alpert, A.S. Dugast, P.W. Parren, F. Nimmerjahn, D.T. Evans, G. Alter, D.N. Forthal, J.E. Schmitz, S. Iida, P. Poignard, D.I. Watkins, A.J. Hessell, and D.R. Burton. 2012. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 86:6189-6196.
  • Nimmerjahn, F., and J.V. Ravetch. 2012. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 12:13.
  • Ruiz-Heiland, G., A. Horn, P. Zerr, W. Hofstetter, W. Baum, M. Stock, J.H. Distler, F. Nimmerjahn, G. Schett, and J. Zwerina. 2012. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 71:400-407.
  • Schwab, I., M. Biburger, G. Kronke, G. Schett, and F. Nimmerjahn. 2012. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 42:826-830.
  • Schwab, I., M. Seeling, M. Biburger, S. Aschermann, L. Nitschke, and F. Nimmerjahn. 2012. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol 42:3302-3309.
  • Uderhardt, S., M. Herrmann, O.V. Oskolkova, S. Aschermann, W. Bicker, N. Ipseiz, K. Sarter, B. Frey, T. Rothe, R. Voll, F. Nimmerjahn, V.N. Bochkov, G. Schett, and G. Kronke. 2012. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 36:834-846.

Research of the Nimmerjahn group is funded in the context of the following projects:

  • DFG TRR130/P13: Understanding the role of the human inhibitory FcR for autoreactive and protective humoral immune responses in vivo (2017-2021)
  • DFG SFB1181/A07: Investigating the molecular and cellular pathways of intravenous immunoglobulin G mediated resolution of established autoimmune inflammation (2019-2024)
  • DFG FOR2953: Role of α2,6-linked sialic acids on B cell development and antibody function (2019-2022)
  • DFG D-A-CH: Human IgG Subclass Glycosylation (2019-2021)
  • DFG FOR2886/B2: IgG glycosylation as a regulative factor controlling onset of RA (2019-2021)
  • DFG LU877/19-1: Pathogenicity of IgA antibodies in pemphigoid disease (2020-2022)
  • NIH U19 Centre for Excellence in Translational Research: Consortium for Immunotherapeutics against Emerging Viral Threats (2018-2023)
  • NIH RFA-AI-18-042: Fc-dependent mechanisms of antibody-mediated killing (2019-2024)